VP of Medicinal Chemistry at Pfizer to speak at Drug Design Medicinal Chemistry Meeting Oct 19 2011

Aug. 16, 2011 - PRLog -- Suvit Thaisrivongs, Head of Medicinal Chemistry, Immunology and Autoimmunity Research at Pfizer will give a featured presentation on “Kinase Drug Discovery and Development:  Inflammation Indication Case Studies” at the 5th Drug Design and Medicinal Chemistry Conference to be held in San Diego, CA on October 19-21, 2011 by GTC.

Dr. Thaisrivongs will discuss two examples of the discovery and development of kinase inhibitors against two targets, P38 and JAK. These clinical candidates are in phase 2 and phase 3 clinical studies against a number of non-oncology inflammatory diseases. Below is a few points Dr. Thaisrivongs will touch in his presentation:
•   Examples of kinase inhibitory clinical candidates in late-stage clinical trials for non-oncology uses
•   Drug candidates against promising targets such as P38 and JAK
•   Lead optimization from high-throughput screen, original hits
•   Structure-based drug design with crystal structures of ligand / enzyme complexes
•   Potential First-in-class drugs of these targets

Suvit Thaisrivongs is Head of Medicinal Chemistry for Immunology & Autoimmunity Research at the Pfizer Cambridge research site.  With 28 years of pharmaceutical research experience, he has led chemistry groups that delivered multiple drug candidates in various disease areas, including Cardiovascular Diseases, Infectious Diseases, Central Nervous System, Oncology, Inflammation & Immunology, Allergy & Respiratory.  He has been a management line leader of all integrated chemistry disciplines, and has experience in cross-partner line integrated Research portfolio teams that manage NCE to Phase 2 POC.  He is the inventor of tipranavir (APTIVUSR), an HIV protease inhibitor anti-AIDS medicine.

The 5th Drug Design and Medicinal Chemistry Conference will discuss strategies for hit and target identification, fragment based drug design, chemoinformatics, protein-protein interactions, ligand based drug design, computer aided drug design, protein flexibility, high performance computing, covalent inhibitors, mutational resistance, selectivity of kinase inhibitors, potency, specificity, lead optimization, ADMET, safety in drug discovery, advances in drug delivery and much more.

This conference is part of the 7th Modern Drug Discovery & Development Summit, which includes three other concurrent tracks: 5th Biomarker Discovery & Development, 5th Advances in Stem Cell Discovery & Development and 4th Protein Discovery & Therapeutics.

Wednesday, October 19 will be dedicated to a Plenary Keynote session. Thursday, October 20 and Friday, October 21 will be dedicated to the four individual conference tracks of the summit.

For more information, please visit www.gtcbio.com